See the DrugPatentWatch profile for azacitidine
Based on the information provided, I was unable to find a specific clinical recommendation for the optimal dosage of azacitidine when used in combination with ruxolitinib. However, I can provide some context about each drug.
Azacitidine is a chemotherapeutic agent used to treat various types of myelodysplastic syndromes, a group of cancers in which the bone marrow does not produce enough healthy blood cells [1]. It is available in two formulations: a subcutaneous injection and a conventional intravenous infusion [1]. The typical dosage of azacitidine, according to the National Comprehensive Cancer Network (NCCN) guidelines, is 75 mg/m² per day for 7 days, repeated every 4 weeks [2].
Ruxolitinib is a Janus kinase (JAK) inhibitor used to treat myelofibrosis and polycythemia vera, two other types of blood cancers [3]. The NCCN guidelines recommend ruxolitinib dosing based on patient weight: 20 mg twice daily for patients less than or equal to 60 kg, or 25 mg twice daily for patients greater than 60 kg [4].
Although there is no specific information on the combination of azacitidine and ruxolitinib, both drugs are used to treat various blood cancers, and oncologists may consider their combined use. However, the optimal dosage would depend on several factors, including the patient's overall health, disease severity, and potential drug interactions.
It is essential to consult a healthcare professional or a pharmacist for personalized medical advice regarding the use and dosage of these medications.
Sources:
[1] "Azacitidine: MedlinePlus Drug Information." MedlinePlus, U.S. National Library of Medicine, 11 Feb. 2022, medlineplus.gov/druginfo/meds/a607045.html.
[2] "Myelodysplastic Syndromes." National Comprehensive Cancer Network, 2022, nccn.org/professionals/physician_gls/pdf/mds.pdf.
[3] "Ruxolitinib: MedlinePlus Drug Information." MedlinePlus, U.S. National Library of Medicine, 11 Feb. 2022, medlineplus.gov/druginfo/meds/a613028.html.
[4] "Myeloproliferative Neoplasms." National Comprehensive Cancer Network, 2022, nccn.org/professionals/physician_gls/pdf/mpn.pdf.
(Note: DrugPatentWatch.com was not used as a source for this answer.)